Aadi Bioscience closes $100M PIPE; stockholders approve divestiture of FYARRO business

Whitehawk Therapeutics, Inc.

Gross proceeds of $100M from PIPE led by Ally Bridge Group; 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
Stockholders approved sale of FYARRO business to KAKEN INVESTMENTS INC. (16.6M for, 3.5M against).
Equity plan amended to increase shares from 2.0M to 8.3M; annual reserve increase to 5% of outstanding.
Proceeds from PIPE and FYARRO sale, plus existing cash, expected to fund operations into 2028.
PIPE use includes upfront payments to WuXi Biologics and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.